Efficacy and safety of semaglutide in glycemic control, body weight management, lipid profiles and other biomarkers among obese type 2 diabetes patients initiated or switched to semaglutide from other GLP-1 receptor agonists.
Body weight
Glucagon-like peptide-1 receptor agonists
Incretin
Obesity
Type 2 diabetes
Journal
Journal of diabetes and metabolic disorders
ISSN: 2251-6581
Titre abrégé: J Diabetes Metab Disord
Pays: Switzerland
ID NLM: 101590741
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
18
07
2021
accepted:
07
09
2021
entrez:
13
12
2021
pubmed:
14
12
2021
medline:
14
12
2021
Statut:
epublish
Résumé
Evidence of the efficacy and safety of semaglutide among patients with type 2 diabetes who were initiated on or were switched to semaglutide from other GLP-1 RAs remains limited. The objective of this study was to investigate the short-term effects of switching to semaglutide from other GLP-1 RAs. This retrospective cohort study evaluated patients with type 2 diabetes who were initiated on or were switched to semaglutide due to poor diabetes control with other GLP-1 RAs or other medications, or obesity. HbA1c, body weight, serum creatinine, serum uric acid, parameters of lipid metabolism, and parameters of liver function were measured before and 6 months after administration of semaglutide. A total of 50 patients were registered in the study. After switching to semaglutide (n = 43), HbA1c and body weight significantly decreased ( Semaglutide showed excellent efficacy, even in patients switched from other GLP-1 RAs. Semaglutide appears to be a promising agent for blood glucose and body weight control in obese type 2 diabetes mellitus patients and could be more potent in treating type 2 diabetes than existing GLP-1 RAs.
Identifiants
pubmed: 34900848
doi: 10.1007/s40200-021-00899-9
pii: 899
pmc: PMC8630305
doi:
Types de publication
Case Reports
Langues
eng
Pagination
2121-2128Informations de copyright
© The Author(s) 2021.
Déclaration de conflit d'intérêts
Conflict of interestThe all authors have no conflicts of interest to declare.
Références
Nutr Metab Cardiovasc Dis. 2020 Jun 25;30(7):1106-1114
pubmed: 32448716
Diabetes Metab. 2008 Feb;34 Suppl 2:S49-55
pubmed: 18640586
Diabetes Ther. 2021 Feb;12(2):527-536
pubmed: 33367981
N Engl J Med. 2016 Nov 10;375(19):1834-1844
pubmed: 27633186
Clin Ther. 2015 Jan 1;37(1):225-241.e8
pubmed: 25554560
Diabetes Metab. 2020 Sep;46(4):272-279
pubmed: 32437914
BMC Geriatr. 2017 Oct 16;17(Suppl 1):226
pubmed: 29047372
Clin Exp Ophthalmol. 2016 May;44(4):260-77
pubmed: 26716602
BMJ Open Diabetes Res Care. 2020 Oct;8(2):
pubmed: 33115821
Diabetes Metab. 2020 Apr;46(2):100-109
pubmed: 31539622
Nat Rev Endocrinol. 2018 Feb;14(2):88-98
pubmed: 29219149
Diabetes Care. 2018 Feb;41(2):258-266
pubmed: 29246950
Lancet Diabetes Endocrinol. 2018 Apr;6(4):275-286
pubmed: 29397376
Diabetes Care. 2015 Apr;38(4):604-9
pubmed: 25573883
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Metabolites. 2021 Jan 27;11(2):
pubmed: 33513761
Am J Physiol. 1997 Nov;273(5):E981-8
pubmed: 9374685
Nat Rev Endocrinol. 2018 Jul;14(7):390-403
pubmed: 29728598
Obes Rev. 2019 Jun;20(6):816-828
pubmed: 30972878
J Clin Pharm Ther. 2020 Sep;45 Suppl 1:43-60
pubmed: 32910487
Diabetes Metab. 2019 Oct;45(5):409-418
pubmed: 30615985
JCI Insight. 2020 Mar 26;5(6):
pubmed: 32213703
J Diabetes Metab Disord. 2018 May 23;17(2):85-91
pubmed: 30918840
Diabetes Obes Metab. 2018 Feb;20 Suppl 1:5-21
pubmed: 29364588
Gastroenterology. 2007 May;132(6):2131-57
pubmed: 17498508
Can J Diabetes. 2019 Mar;43(2):136-145
pubmed: 30195966